CCL4 and neoplasm: Previous work performed in genetically modified models indicate that lowered WNT/β-catenin signaling11 resulted in increased intratumoral CCL4 cytokine release, which lead to enhanced influx of CD103+/BATF3+ pDCs and subsequent activation of CD8+ T cell anti-tumor activity.